[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
:: Volume 19, Issue 4 (10-2021) ::
Int J Radiat Res 2021, 19(4): 907-912 Back to browse issues page
Observation of efficacy and prognosis of chemoradiotherapy with apatinib in combination with oxaliplatin + 5-fluorouracil + leucovorin in the gastric cancer in advanced stage
R. Zhang, S. Cao, X. Yu , D. Zhang, S. Cui, C. Liu, X. Cheng, J. Wang
Department of General Surgery II Ward, Linyi Central Hospital, Linyi, Shandong276400, China. , prof.wangcorespond@gmail.com
Abstract:   (236 Views)
Background: To investigate the clinical efficacy of apatinib in combination with oxaliplatin + 5-fluorouracil + leucovorin in clinical chemotherapy for the advanced gastric cancer. Materials and Methods: Between June 2016 and December 2018, we enrolled a total of 92 patients with advanced gastric cancer who were receiving 4500 cGy of radiation through the 5 weeks after resection of adenocarcinoma, and divided them into two groups as per the treatment strategies, with 46 patients in each group. Patients in the control group underwent the regular chemotherapy (oxaliplatin + 5-fluorouracil + leucovorin), while those in the observation group would additionally receive the medication of apatinib. We compared the efficacy, changes in the levels of high-sensitivity C-reactive protein (hs-CRP) and Tumor necrosis factor (TNF-α) in serum, prognosis and adverse reactions between two groups, or before and after treatment. Results: In the observation group, the total effectiveness rate was higher than that in the control group. Also, after treatment, significant decreases were found in levels of high-sensitivity C-reactive protein and TNF-α in serum of patients in the observation group, more evident than those in the control group. Moreover, progression-free survival and total survival durations of patients were significantly longer than those in the control group, while the incidence rate of adverse reaction was reduced sharply (all P < 0.05). Conclusion: our study showed that apatinib combination with oxaliplatin + 5-fluorouracil + leucovorin seems to have promising efficacy, and is worthy of being studied as a new regimen of gastric cancer treatment.
Keywords: Apatinib, oxaliplatin + 5-fluorouracil + leucovorin, chemotherapy, advanced gastric cancer, efficacy, prognosis.
Full-Text [PDF 1724 kb]   (116 Downloads)    
Type of Study: Original Research | Subject: Radiation Biology
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA



XML     Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Zhang R, Cao S, Yu X, Zhang D, Cui S, Liu C, et al . Observation of efficacy and prognosis of chemoradiotherapy with apatinib in combination with oxaliplatin + 5-fluorouracil + leucovorin in the gastric cancer in advanced stage. Int J Radiat Res. 2021; 19 (4) :907-912
URL: http://ijrr.com/article-1-3969-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 19, Issue 4 (10-2021) Back to browse issues page
International Journal of Radiation Research
Persian site map - English site map - Created in 0.04 seconds with 32 queries by YEKTAWEB 4355